Navigation Links
Indevus Pharmaceuticals Announces Release of 2008 Annual Report
Date:1/27/2009

LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com. In addition, the Company's stockholders may obtain a free hard copy of the Annual Report by contacting the Company's Investor Relations department at (781) 861-8444 or by mailing written requests to Indevus Pharmaceuticals, Inc., Attention Investor Relations, 33 Hayden Ave., Lexington, Massachusetts 02421.

The Company's common stock is listed and traded on the NASDAQ Global Market under the symbol "IDEV."

About Indevus Pharmaceuticals

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.

    Contact:
    Michael W. Rogers
    EVP and Chief Financial Officer
    (781) 861-8444

    Robin L. DeCarlo
    Sr. Director, Corporate Communications
    (781) 402-3405


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
2. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
3. Indevus and FDA Agree on Path Forward for NEBIDO(R)
4. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
7. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
8. Indevus Announces Management Changes
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
11. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Including Launch of Key ... Bavituximab Phase II Cancer Program-, TUSTIN, Calif., March ... stage biopharmaceutical,company developing monoclonal antibodies for the treatment of cancer ... third quarter of fiscal year (FY) 2008 ended January 31, ...
... XI,AN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer ... company,within the bionanometer industry has formally signed ... with China Guangzhou,LGLY Advertising LTD., Guangzhou ... agency. It was,founded in December 1997 and ...
... Emerging Nanotechnologies (PEN) and National Science Foundation (NSF) ... the television series Nanotechnology: The Power of Small ... onlywill include remarks by U.S. Senator Ron Wyden ... , The series three programs explore critical questions ...
Cached Biology Technology:Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10CBIU Signs Agreement with LGLY Advertising LTD 2New nanotechnology television series does 'sweat the small stuff' 2
(Date:9/2/2014)... -- A team of University of Maryland physicists ... other scientists say make possible new nanostructures and ... energy and quantum computing advances to new sensor ... of Nature Communications the Maryland scientists, ... for hybrid nanostructures that uses a connector, or ...
(Date:9/2/2014)... a new study that could ultimately lead to many ... Scripps Research Institute (TSRI) have adapted a chemical approach ... molecules that can treat a form of muscular dystrophy. ... and a disease-causing defect as a catalyst to synthesize ... Matthew Disney.,"Because the treatment is synthesized only in diseased ...
(Date:9/2/2014)... COLUMBUS, Ohio New research suggests that professional baseball pitchers ... or more days in a single season because of injury ... their lower back and pelvis. , In the study, 347 ... with more tilt in their pelvis as they raised a ... likely to miss at least 30 days cumulative, not ...
Breaking Biology News(10 mins):New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Scripps Florida scientists make diseased cells synthesize their own drug 2In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3
... show that summertime storms in the southeastern United States shed ... from humans is likely driving that trend. The ... evident in data from NASA,s Tropical Rainfall Measuring Mission satellite, ... more rain and span a larger area across the Southeast ...
... Stowers Institutes Trainor Lab has demonstrated the role of ... nervous system, a process that requires coordination of differentiation ... division that increases their numbers. Until now, the mechanisms ... The findings will be published in the ...
... 28, 2008 -- As organic farming becomes more ... are increasingly important. In a recent study in ... isotopic discrimination to determine if non-organic, synthetic fertilizers ... at the Instituto Murciano de Investigacin y Desarrollo ...
Cached Biology News:NASA data link pollution to rainy summer days in the southeast 2NASA data link pollution to rainy summer days in the southeast 3Trainor Lab characterizes gene essential for prenatal development of nervous system 2Is it organic or not? 2
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... OrientExpress™ System Modules ... and directional cloning into ... expression vectors ... OrientExpress™ Cloning Systems, the ...
... The CHEMICON Re-Blot Western Blot ... of antibodies from Western blots that ... radioactive iodine or other isotopes. It ... substrates (TMB, DAB, 4-chloronapthol, etc.), as ...
Applications: Western blotting ...
Biology Products: